{"id":"NCT02955355","sponsor":"Baxalta now part of Shire","briefTitle":"Long-Term Tolerability and Safety of HYQVIA/HyQvia in CIDP","officialTitle":"Long-Term Tolerability and Safety of Immune Globulin Infusion 10% (Human) With Recombinant Human Hyaluronidase (HYQVIA/HyQvia) for the Treatment of Chronic Inflammatory Demyelinating Polyradiculoneuropathy (CIDP)","status":"COMPLETED","phase":"PHASE3","dates":{"start":"2016-11-14","primaryCompletion":"2023-07-04","completion":"2023-07-04","firstPosted":"2016-11-04","resultsPosted":"2024-08-28","lastUpdate":"2024-08-28"},"enrollment":85,"design":{"allocation":"NA","model":"SINGLE_GROUP","masking":"NONE","primaryPurpose":"TREATMENT"},"conditions":["Chronic Inflammatory Demyelinating Polyradiculoneuropathy"],"interventions":[{"type":"BIOLOGICAL","name":"HYQVIA","otherNames":["10%) with recombinant human hyaluronidase (rHuPH20)","Immune Globulin Infusion 10% (Human) (IGI","IGI"]}],"arms":[{"label":"HYQVIA/HyQvia","type":"EXPERIMENTAL"}],"summary":"Adults with Chronic Inflammatory Demyelinating Polyradiculoneuropathy (CIDP) who have completed study 161403 will be able to take part in this study.\n\nThe main aim of the study is to evaluate side effects in the long-term treatment with HYQVIA/HyQvia.\n\nAll participants will receive HYQVIA/HyQvia in the same way as they were receiving in study 161403. The dosing interval of HYQVIA/HyQvia can be adjusted after 12 weeks of treatment in study 161505 if the study doctor determines that it is safe to do so.\n\nParticipants will visit the clinic within 1 week after the first and second dose of HYQVIA/HyQvia and then every 12 weeks for the duration of the study.","primaryOutcome":{"measure":"Number of Participants With Any Treatment-emergent Serious Adverse Events (SAEs) and Adverse Events (AEs), Regardless of Causality","timeFrame":"From the first dose of study drug up to end of study (up to 6.6 years)","effectByArm":[{"arm":"HYQVIA/HyQvia","deltaMin":76,"sd":null}],"pValues":[]},"eligibility":{"minAge":"18 Years","sex":"ALL","healthyVolunteers":false,"inclusionCount":null,"exclusionCount":null},"locations":{"siteCount":35,"countries":["United States","Argentina","Brazil","Canada","Colombia","Czechia","Denmark","France","Germany","Greece","Italy","Mexico","Poland","Serbia","Slovakia","Spain","Turkey (TÃ¼rkiye)","United Kingdom"]},"refs":{"pmids":[],"seeAlso":["https://clinicaltrials.takeda.com/study-detail/5f6b5fc54db2bf003ab45c9a"]},"adverseEventsSummary":{"seriousAny":{"events":20,"n":85},"commonTop":["Headache","COVID-19","Pyrexia","Infusion site erythema","Arthralgia"]}}